標(biāo)題: Titlebook: Continuous Dopaminergic Stimulation in Parkinson’s Disease; Proceedings of the W J. A. Obeso,R. Horowski,C. D. Marsden Conference proceedin [打印本頁] 作者: VER 時間: 2025-3-21 19:09
書目名稱Continuous Dopaminergic Stimulation in Parkinson’s Disease影響因子(影響力)
書目名稱Continuous Dopaminergic Stimulation in Parkinson’s Disease影響因子(影響力)學(xué)科排名
書目名稱Continuous Dopaminergic Stimulation in Parkinson’s Disease網(wǎng)絡(luò)公開度
書目名稱Continuous Dopaminergic Stimulation in Parkinson’s Disease網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Continuous Dopaminergic Stimulation in Parkinson’s Disease被引頻次
書目名稱Continuous Dopaminergic Stimulation in Parkinson’s Disease被引頻次學(xué)科排名
書目名稱Continuous Dopaminergic Stimulation in Parkinson’s Disease年度引用
書目名稱Continuous Dopaminergic Stimulation in Parkinson’s Disease年度引用學(xué)科排名
書目名稱Continuous Dopaminergic Stimulation in Parkinson’s Disease讀者反饋
書目名稱Continuous Dopaminergic Stimulation in Parkinson’s Disease讀者反饋學(xué)科排名
作者: Pruritus 時間: 2025-3-21 20:40 作者: 驚惶 時間: 2025-3-22 02:12 作者: 參考書目 時間: 2025-3-22 05:52 作者: 射手座 時間: 2025-3-22 11:38
Verfassung und Nation in der Bundesrepublik treated with subcutaneous lisuride using a portable infusion pump. All patients improved initially during the first weeks of treatment. Four patients abandoned the trial within the first few weeks as a consequence of psychiatric complications (2 cases), inability to understand how to use the pump (作者: MAL 時間: 2025-3-22 13:27 作者: MAL 時間: 2025-3-22 17:20 作者: conspicuous 時間: 2025-3-22 23:11 作者: emission 時間: 2025-3-23 01:49 作者: prolate 時間: 2025-3-23 06:09 作者: 革新 時間: 2025-3-23 13:41 作者: Pericarditis 時間: 2025-3-23 16:13
Virtuelle Gruppen und reale Netzeicant. When this occurs early in the course of treatment, there is usually a history of prior psychotic illness. Chronic treatment can, however, elicit psychosis in individuals without such a history. The possible pathogenesis of this is reviewed.作者: 合群 時間: 2025-3-23 20:26
die Urbanisierung der Online-Gemeinschaftne agonists. This article reviews those technologies which can be applied to Parkinson’s disease, both for targetting the central nervous system with drugs, as well as for matching the appropriate rate controlled delivery with therapeutic needs. In particular, the possibility exists for eliminating 作者: 滑稽 時間: 2025-3-24 00:56 作者: Negligible 時間: 2025-3-24 04:15
René K?nig Schriften. Ausgabe letzter Handrepeated administration of L-DOPA or bromocriptine to rodents have shown increases, decreases or no change in brain dopaminergic activity. For this reason we have re-examined the effects of chronic L-DOPA or dopamine agonist administration on brain dopamine receptor function in rats..Repeated intrap作者: CON 時間: 2025-3-24 07:10 作者: FEIGN 時間: 2025-3-24 10:56
Continuous Dopaminergic Stimulation in Parkinson’s Disease978-3-7091-8954-2Series ISSN 0303-6995 作者: puzzle 時間: 2025-3-24 17:17 作者: 冬眠 時間: 2025-3-24 19:23 作者: ineptitude 時間: 2025-3-25 02:03
Journal of Neural Transmission. Supplementahttp://image.papertrans.cn/c/image/236996.jpg作者: 連系 時間: 2025-3-25 04:17
The case for and concerns about continuous dopamine stimulation in Parkinson’s diseaseluctations in response (“on-off”). This should be manageable with innovative delivery systems for the drugs. However further studies are required to determine if continuous dopaminergic stimulation will be complicated by increased levels of drug metabolites or down regulation of dopaminergic neurotransmission.作者: 極小 時間: 2025-3-25 09:59
Psychiatric side effects during the treatment of Parkinson’s diseaseicant. When this occurs early in the course of treatment, there is usually a history of prior psychotic illness. Chronic treatment can, however, elicit psychosis in individuals without such a history. The possible pathogenesis of this is reviewed.作者: defenses 時間: 2025-3-25 15:27 作者: Airtight 時間: 2025-3-25 17:41 作者: 砍伐 時間: 2025-3-25 20:15 作者: jumble 時間: 2025-3-26 03:53 作者: COST 時間: 2025-3-26 07:49
Applications of new drug delivery technologies to Parkinson’s disease and dopaminergic agentsdictable swings in therapeutic efficacy in Parkinson patients with the “on/off” effect, but may even have a role in the future in preventing such fluctuations from developing in patients chronically treated with dopaminergic therapies.作者: acolyte 時間: 2025-3-26 10:10
Conference proceedings 1988ontinuous s.c. infusion of lisuride, a watersoluble dopaminergic 8- -aminoergoline with dopaminergic properties which can be injected or infused, can improve - sometimes quite considerably - motor function in severely disabled fluctuating Parkinsonian patients. The concurrent use of the peripheral d作者: BRUNT 時間: 2025-3-26 13:16 作者: 協(xié)定 時間: 2025-3-26 18:47 作者: Glower 時間: 2025-3-26 22:38
https://doi.org/10.1007/978-3-322-80731-1infusion together with a small dose of levodopa (plus DDI) are effective treatment for “on-off” fluctuations in Parkinson’s disease, but the frequency of adverse effects limits the number of patients who can be treated successfully with this technique.作者: Wernickes-area 時間: 2025-3-27 03:04 作者: 畢業(yè)典禮 時間: 2025-3-27 07:14 作者: 獨白 時間: 2025-3-27 11:00
Continuous subcutaneous lisuride infusions in Parkinson’s diseaseinfusion together with a small dose of levodopa (plus DDI) are effective treatment for “on-off” fluctuations in Parkinson’s disease, but the frequency of adverse effects limits the number of patients who can be treated successfully with this technique.作者: 不可思議 時間: 2025-3-27 14:18
Pharmacokinetics of lisuride after subcutaneous infusiontion of the infusion, concentrations declined with a half-life of 1.4 ± 0.4 hour. The total clearance of lisuride was 20 ± 6 ml/min/kg. Due to the low interpatient variability of plasma levels, a good control of clinical effects is to be expected.作者: BOOM 時間: 2025-3-27 18:32
Lisuride infusion pump in Parkinson’s disease. A report of two casesough a net increase in the number of hours spent “on”. Dyskinesias remained unmodified. Limiting psychiatric side effects were observed in one of the patients..Practical and technical aspects of the management of this therapeutic method are discussed.作者: cancellous-bone 時間: 2025-3-28 00:15
Pathogenetic studies of motor fluctuations in Parkinson’s diseasete advanced Parkinson’s disease. Since levodopa clearance from the general circulation was found to be similar in patients with wearing-off or on-off phenomena and those with a stable response to levodopa, peripheral pharmacokinetic factors are unlikely to be involved. Efficacy half-time for levodop作者: Employee 時間: 2025-3-28 05:37
The case for and concerns about continuous dopamine stimulation in Parkinson’s diseaseluctations in response (“on-off”). This should be manageable with innovative delivery systems for the drugs. However further studies are required to determine if continuous dopaminergic stimulation will be complicated by increased levels of drug metabolites or down regulation of dopaminergic neurotr作者: jabber 時間: 2025-3-28 07:24 作者: 激勵 時間: 2025-3-28 12:56 作者: 正常 時間: 2025-3-28 16:59
Chronic s.c. Lisuride in Parkinson’s disease — motorperformance and avoidance of psychiatric side ef L-deprenyl. L-Dopa infusions are efficient, but not applicable for longer use. S. c.-Lisuride-infusions reduce markedly motor-response fluctuations, dystonias and hyperkinesias, but bear the risk of inducing confusion or even psychosis. In patients with coexisting response fluctuations and psychiat作者: 集聚成團 時間: 2025-3-28 22:00
Continuous subcutaneous lisuride infusions in Parkinson’s diseasewith continuous (24 hour) subuctaneous lisuride infusions together with a reduced dose of levodopa (plus DDI). An improvement in motor performance was seen in 10 patients, with a mean increase in percentage of waking time spent “on” of 32 per cent (range 13–59 percent). However, adverse effects were作者: BAN 時間: 2025-3-29 01:32
A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson’s disease-release form, Madopar HBS, which attenuated fluctuations in patients with end-of-dose impairment, but achieved only moderate improvement in patients with on-off phenomena..In a second phase of the trial, 4 parkinsonians exhibiting the most severe fluctuations of mobility and the poorest response to作者: CLAP 時間: 2025-3-29 03:07 作者: Aspirin 時間: 2025-3-29 10:48
Lisuride infusion pump in Parkinson’s disease. A report of two cases treated with Lisuride by means of a portable subcutaneous infusion pump are reported..Results obtained show significant improvement in disability through a net increase in the number of hours spent “on”. Dyskinesias remained unmodified. Limiting psychiatric side effects were observed in one of the 作者: 背心 時間: 2025-3-29 11:23 作者: 紅潤 時間: 2025-3-29 17:49 作者: 600 時間: 2025-3-29 22:52 作者: 提名的名單 時間: 2025-3-30 02:59 作者: 鞭打 時間: 2025-3-30 06:59
Effect of chronic subcutaneous minipump infusion of lisuride upon locomotor activity of ratscomotor activity was measured at 5 hours, 1, 7 and 14 days after implantation. Thereafter the minipumps were removed and 1, 7 and 21 days later the locomotor activity was recorded after a subcutaneous challenge dose of lisuride 0.1 mg/kg. In the course of continuous infusion the lisuride-treated rat作者: 蓋他為秘密 時間: 2025-3-30 09:20 作者: 暴露他抗議 時間: 2025-3-30 12:43 作者: Decline 時間: 2025-3-30 19:45 作者: fibula 時間: 2025-3-30 23:55 作者: 新娘 時間: 2025-3-31 03:37 作者: CAGE 時間: 2025-3-31 08:57
https://doi.org/10.1007/978-3-322-80866-0 the lesioned and implanted side. The infusion of dopamine reversed reserpine-induced akinesia only when pargyline was associated. In the range of concentration used, maximum allowed by solubility of compounds, the effects of dopamine were more potent than those of the agonists. In spite of the stab作者: Obliterate 時間: 2025-3-31 11:47
René K?nig Schriften. Ausgabe letzter HandSimilarly, no effects were observed on striatal dopamine function following one year’s administration of bromocriptine. Pergolide produced an enhancement of apomorphine-induced stereotypy but a decrease in D-2 receptor density as judged by 3H-spiperone binding..In rats with a unilateral 6-OHDA lesio作者: Integrate 時間: 2025-3-31 13:58 作者: 充足 時間: 2025-3-31 17:30
Treatment of Parkinson’s disease with subcutaneous lisuride infusions
